论文部分内容阅读
目的探讨埃索美拉唑治疗消化性溃疡患者的临床效果。方法选取2013年1月至2015年1月辽宁省抚顺市第二医院收治的152例消化性溃疡患者作为研究对象,按随机数字表法将其分为观察组和对照组,各76例。观察组患者采用以埃索美拉唑作为主药的3联疗法进行治疗,对照组患者应用以奥美拉唑作为主药的3联疗法,比较两组患者的临床疗效、症状积分。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后4、8周,观察组患者的症状积分均明显低于对照组,差异均有统计学意义(均P<0.05)。结论采用以埃索美拉唑作为主药的3联疗法治疗消化性溃疡患者临床疗效明显,能够有效降低患者的症状积分,改善预后,提高其生命质量。
Objective To investigate the clinical effect of esomeprazole in patients with peptic ulcer. Methods A total of 152 patients with peptic ulcer admitted to the Second Hospital of Fushun, Liaoning Province between January 2013 and January 2015 were enrolled in this study. They were divided into observation group and control group by random number table method, with 76 cases in each group. Patients in the observation group were treated with triple therapy with esomeprazole as the main drug, and patients in the control group were treated with triple therapy with omeprazole as the primary drug. Clinical efficacy and symptom scores were compared between the two groups. Results The total effective rate of observation group was significantly higher than that of the control group (P <0.05). At 4 and 8 weeks after treatment, symptom scores of the observation group were significantly lower than those of the control group Significance (both P <0.05). Conclusion The triple therapy with esomeprazole as the main drug has obvious curative effect on patients with peptic ulcer, which can effectively reduce the patients’ symptom scores, improve prognosis and improve their quality of life.